Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
Aged
Biomarkers
/ blood
Blood Proteins
Echocardiography
Female
Galectin 3
/ blood
Galectins
Heart Failure
/ metabolism
Heart Ventricles
Humans
Interleukin-1 Receptor-Like 1 Protein
/ blood
Male
Middle Aged
Myocardial Infarction
/ metabolism
Percutaneous Coronary Intervention
Prospective Studies
ROC Curve
Reproducibility of Results
ST Elevation Myocardial Infarction
/ metabolism
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
04
2019
accepted:
23
08
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
17
4
2020
Statut:
epublish
Résumé
To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e', and E/e') in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year. Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719.
Identifiants
pubmed: 31687050
doi: 10.1155/2019/9529053
pmc: PMC6811795
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Galectin 3
0
Galectins
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
LGALS3 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT03735719']
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
9529053Informations de copyright
Copyright © 2019 Agata Tymińska et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Int J Cardiol. 2018 Nov 1;270:336-342
pubmed: 29954670
Circulation. 2008 Apr 15;117(15):1936-44
pubmed: 18378613
J Am Coll Cardiol. 2014 Jan 21;63(2):158-66
pubmed: 24076531
Circulation. 2000 Jun 27;101(25):2981-8
pubmed: 10869273
Int J Cardiol. 2014;172(1):e98-e101
pubmed: 24433619
Clin Chem. 2012 Jan;58(1):267-73
pubmed: 22110019
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Am J Cardiol. 2015 Apr 2;115(7 Suppl):26B-31B
pubmed: 25665762
Clin Chim Acta. 2016 Jan 15;452:50-7
pubmed: 26528636
Cardiol J. 2013;20(6):577-82
pubmed: 24338533
Eur Heart J. 2012 Oct;33(20):2569-619
pubmed: 22922416
J Atheroscler Thromb. 2012;19(12):1073-82
pubmed: 23037954
Adv Clin Exp Med. 2016 Jul-Aug;25(4):617-23
pubmed: 27629834
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
J Am Coll Cardiol. 2018 Dec 25;72(25):3246-3254
pubmed: 30573026
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Heart. 2016 Jul 15;102(14):1134-41
pubmed: 27084804
J Am Coll Cardiol. 2017 Nov 7;70(19):2378-2388
pubmed: 29096809
Kardiol Pol. 2018;76(6):1012-1014
pubmed: 29905365
Pol Arch Intern Med. 2019 Feb 28;129(2):106-116
pubmed: 30648697
Heart. 2017 Jan 1;103(1):71-77
pubmed: 27465055
Int J Cardiol. 2014;172(1):e250-2
pubmed: 24467978
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
Circulation. 2002 Dec 3;106(23):2961-6
pubmed: 12460879
Circ Heart Fail. 2013 Mar;6(2):219-26
pubmed: 23395934
Circ Heart Fail. 2013 May;6(3):492-8
pubmed: 23505301
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
Am J Cardiol. 2017 Jun 15;119(12):2021-2029
pubmed: 28434647
Expert Rev Mol Med. 2008 Jun 13;10:e17
pubmed: 18549522
Eur J Heart Fail. 2013 May;15(5):511-8
pubmed: 23291728
Eur J Heart Fail. 2009 Sep;11(9):811-7
pubmed: 19648160
BMJ. 2015 Mar 04;350:h910
pubmed: 25740799
Ann Med. 2011 Feb;43(1):60-8
pubmed: 21189092
Cardiovasc Res. 2009 Feb 15;81(3):482-90
pubmed: 19050008
Am J Cardiol. 2016 Aug 15;118(4):535-42
pubmed: 27374606
Biochim Biophys Acta. 2013 Dec;1832(12):2403-13
pubmed: 23851052
Am J Med. 2017 Sep;130(9):1112.e9-1112.e15
pubmed: 28344136
Biomarkers. 2016;21(3):225-32
pubmed: 26767401